A novel method for developing diagnostic tools and treatments for pancreatitis through the use of a truncated pancreatitis-associated protein (PAP).
Background: Acute pancreatitis ranges in severity from a mild, self-limiting course treated with conservative methods, to a more aggressive variety causing sepsis, pancreatic necrosis, and hemorrhage. Approximately 25% of acute pancreatitis cases will progress in severity and require surgery. The regeneration (Reg) family of proteins, which include Reg I (pancreatic stone protein) and Reg III (pancreatitis-associated protein – “PAP”), are a family of proteins minimally expressed in the normal pancreas but strongly induced in acute pancreatitis. Studies show that inhibition of Reg/PAP expression significantly worsens pancreatitis. Furthermore, histopathologic evaluation of the pancreas reveals worsened edema, elevated leukocyte infiltration, and fat necrosis after antisense-treatment.
Technology Overview: This technology enables the diagnosis and treatment of pancreatitis through the use of a truncated PAP. For example, the technology provides several methods for developing treatments based on various proteins. The technology can also enable the development of a method for screening candidate pancreatitis treatments. This includes providing a mammal with a pancreatitis condition, administering to the mammal an amount of a candidate pancreatitis-associated protein having a truncated form, and observing a result. In addition, the technology provides a method for making an antibody to portions of pancreatitis-associated protein to serve as a diagnostic tool for use in pancreatitis.
https://suny.technologypublisher.com/files/sites/adobestock_573567320.jpeg
Advantages: • Provides a novel method for treating pancreatitis. • Versatile – enables methods for both diagnosing and treating pancreatitis, as well as screening candidate pancreatitis treatments.
Applications: The primary applications for this technology are the development of diagnostic tools and treatments for pancreatitis. This includes screening candidate pancreatitis treatments.
Intellectual Property Summary: Issued United States Patent: US8,012,928
Stage of Development: TRL 3 - Experimental proof of concept
Licensing Status: This technology is available for licensing.
Licensing Potential: This technology would be of interest to anyone involved in the development of pancreatitis diagnostic tools and treatments, including: • Pharmaceutical companies. • Hospitals. • Medical research facilities. • Universities.